Cytokinesis-blocked micronucleus cytome assay biomarkers identify lung cancer cases amongst smokers

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 5, 2008, Pages 1111-1119

  El Zein, Randa A ^a   Fenech, Michael ^b   Lopez, Mirtha S ^a   Spitz, Margaret R ^a   Etzel, Carol J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; DIAGNOSTIC AGENT; NITROSAMINE; TUMOR MARKER;

ARTICLE; CANCER RISK; CELL DEATH; CELL DIVISION; CHROMOSOME DAMAGE; CIGARETTE SMOKING; CONTROLLED STUDY; CYTOKINESIS; FEMALE; GENETIC DAMAGE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MICRONUCLEUS TEST; MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; APOPTOSIS; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CHROMOSOME ABERRATION; DNA DAMAGE; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MICRONUCLEUS; MIDDLE AGED; QUESTIONNAIRE; RISK FACTOR; SMOKING; STATISTICAL MODEL;

APOPTOSIS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHROMOSOME ABERRATIONS; CYTOKINESIS; DNA DAMAGE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; MIDDLE AGED; NITROSAMINES; QUESTIONNAIRES; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 52649132933     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2827     Document Type: Article

References (45)

1. Hirsch FR, Fischer JR, Niklinski J, Zochbauer-Muller S. Future developments in the treatment of lung cancer. Lung Cancer 2002;38:S81-5.
2. Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science 1991;254:1153-60.
3. Liou SH, Lung JC, Chen YH, et al. Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area. Cancer Res 1999;59:1481-4.
4. Bonassi S, Hagmar L, Stromberg U, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res 2000;60:1619-25.
5. Bonassi S, Znaor A, Norppa H, Hagmar L. Chromosomal aberrations and risk of cancer in humans: an epidemiologic perspective. Cytogenet Genome Res 2004;104:376-82.
6. Smerhovsky Z, Landa K, Rossner P, et al. Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations. Environ Health Perspect 2001;109:41-5.
7. Tucker JD, Preston RJ. Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutat Res 1996;365:147-59.
8. Fenech M. The in vitro micronucleus technique. Mutat Res 2000;455:81-95.
9. Fenech M. Chromosomal biomarkers of genomic instability relevant to cancer. Drug Discov Today 2002;7:1128-37.
10. Kirsh-Volders M, Fenech M. Inclusion of micronuclei in non-divided mononuclear lymphocytes and necrosis/apoptosis may provide a more comprehensive cytokinesis block micronucleus assay for biomonitoring purposes. Mutagenesis 2001;16:51-8.
11. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc 2007;2:1084-104.
12. Umegaki K, Fenech M. Cytokinesis-block micronucleus assay in WIL2-NS cells: a sensitive system to detect chromosomal damage induced by reactive oxygen species and activated human neutrophils. Mutagenesis 2000;15:261-9.
13. Stewenius Y, Gorunova L, Jonson T, et al. Structural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarity. Proc Natl Acad Sci U S A 2005;102:5541-6.
14. Fenech M. Biomarkers of genetic damage for cancer epidemiology. Toxicology 2002;181-2:411-6.
15. Fenech M, Crott J, Turner J, Brown S. Necrosis, apoptosis, cytostasis and DNA damage in human lymphocytes measured simultaneously within the cytokinesis-block micronucleus assay: description of the method and results for hydrogen peroxide. Mutagenesis 1999;14:605-12.
16. Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 2003;12:689-98.
17. Hoffmann D, Hoffmann I, El Bayoumy K. Less harmeful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 2001;14:767-90.
18. Thun MJ, Lally CA, Flannery JT, Jr. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997;89:1580-6.
19. Hecht SS, Hoffmann D. The relevance of tobacco specific nitrosamines to human cancer. Cancer Surv 1989;8:273-94.
20. Adams JD, O'Mara-Adams, Hoffmann D. Toxic and carcinogenic agents in undiluted mainstream smoke and side-stream smoke of different types of cigarettes. Carcinogenesis 1987;8:729-31.
21. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
22. Weitberg AB, Corvese D. Oxygen radicals potentiate the genetic toxicity of tobacco-specific nitrosamines. Clin Genet 1993;43:88-91.
23. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-97.
24. Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res 1999;424:127-42.
25. Kaina B. Critical steps in alkylation-induced aberration formation. Mutat Res 1998;404:119-24.
26. 6- methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res 1997;381:227-41.
27. Kaina B. Mechanisms and consequences of methylating agent-induced SCEs and chromosomal aberrations: a long road traveled and still a far way to go. Cytogenet Genome Res 2004;104:77-86.
28. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907-22.
29. Cloutier JF, Drouin R, Weinfeld M, O'Connor TR, Castonguay A. Characterization and mapping of DNA damage induced by reactive metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) at nucleotide resolution in human genomic DNA. J Mol Biol 2001;313:539-57.
30. El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD, Spitz MR. Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res 2006;66:6449-56.
31. Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985;147:29-36.
32. Abdel-Rahman SZ, El Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 2000;159:63-71.
33. Hill CE, Affatato AA, Wolfe KJ, et al. Gender differences in genetic damage induced by the tobacco-specific nitrosamine NNK and the influence on the Thr241Met polymorphism in the XRCC3 gene. Environ Mol Mutagen 2005;4:22-9.
34. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, Zeiger E. HUMN Project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 2003;534:65-75.
35. Eastmond DA, Tucker JD. Kinetochore localization in micronucleated cytokinesis-blocked Chinese hamster ovary cells: a new and rapid assay for identifying aneuploidy-inducing agents. Mutat Res 1989;224:517-25.
36. Brown R, Pinkerton R, Tuttle M. Respiratory infections in smokers. Am Fam Physician 1987;36:133-40.
37. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.
38. Fruehauf JP, Meyskens FL, Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res 2007;13:789-94.
39. Baskaran K, Laconi S, Reddy MK. Transformation of hamster pancreatic duct cells by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in vitro. Carcinogenesis 1994;15:2461-6.
40. Tithof PK, Elgayyar M, Schuller HM, Barnhill M, Andrews R. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, a nicotine derivative, induces apoptosis of endothelial cells. Am J Physiol Heart Circ Physiol 2001;281:1946-54.
41. Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002;2:455-63.
42. Schuller HM, Plummer HK, Jull BA. Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells. Anat Rec A Discov Mol Cell Evol Biol 2003;270:51-8.
43. Bhagwat SV, Vijayasarathy C, Raza H, Mullick J, Avadhani NG. Preferential effects of nicotine and 4-(N-methyl-N-nitrosamine)-1-(3-pyridyl)- 1-butanone on mitochondrial glutathione S-transferase A4-4 induction and increased oxidative stress in the rat brain. Biochem Pharmacol 1998;56:831-9.
44. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 2004;279:40209-19.
45. Fenech M, Perepetskaya G, Mikhalevich L. A more comprehensive application of the micronucleus technique for biomonitoring of genetic damage rates in human populations - experiences from the Chernobyl catastrophe. Environ Mol Mutagen 1997;30:112-8.